axonics.com - AXNX Company Value to Revenue Ratio

The EV/Sales valuation on the GURU.Markets chart demonstrates the enterprise value to sales ratio, where the current value is 21206.90. Axonics, Inc. (AXNX) has created a unique neuromodulation environment, maintaining market dominance through surgeon certification. The company generates revenue from the sale of implants for the therapy of pelvic dysfunction. Patent protection and a deal with a major medtech behemoth make this niche virtually inaccessible to new players.
AXNX (Axonics Modulation Technologies): analytical breakdowns and indicator data

This indicator measures the total business value minus net debt relative to sales volume, revealing a critical gap between market expectations and actual cash flow generation. By analyzing the Enterprise Value to revenue ratio, an investor can assess the justification for the capitalization premium, which for Axonics, Inc. (AXNX) is supported by strong pricing power and the uniqueness of its rechargeable stimulators.